Every Form 4 that Collegium Pharmaceutical, Inc. (COLL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow COLL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COLL filings page.
COLLEGIUM PHARMACEUTICAL, INC director Gino Santini exercised stock options to acquire 8,700 shares of Common Stock at $16.49 per share. These options were fully vested and exercisable. After the transaction, Santini directly holds 112,483 shares of Common Stock, and the exercised option covering 8,700 shares is fully used.
Collegium Pharmaceutical director John Gordon Freund reported a small open-market sale of common stock. On May 18, 2026, he sold 20 shares of Collegium Pharmaceutical common stock at $34.05 per share in a direct transaction.
After this sale, he directly held 83,952 common shares. The filing also shows indirect interests in entities holding 8,625 shares through Skyline Venture Management V, LLC and 23,129 shares through John Freund Family Partnership IV, L.P., with beneficial ownership disclaimed except for his proportionate pecuniary interest.
Lurker Nancy reported acquisition or exercise transactions in this Form 4 filing.
Collegium Pharmaceutical director Nancy Lurker received a grant of 8,741 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest on the earlier of May 14, 2027, or the company’s 2027 annual shareholder meeting, if she continues serving as a director.
After this equity award, Lurker’s direct holdings total 26,758 shares of common stock. The RSUs will be settled in shares on vesting or, if she so elects, upon the earlier of her board service ending, her death or disability, or a change in control of Collegium Pharmaceutical.
Paya Carlos V reported acquisition or exercise transactions in this Form 4 filing.
COLLEGIUM PHARMACEUTICAL, INC director Carlos V. Paya reported a compensation-related equity grant. He received 8,741 restricted stock units (RSUs), each representing one share of common stock, increasing his direct holdings to 28,323 shares after the award.
The RSUs vest on the earlier of May 14, 2027, or the company’s 2027 Annual Meeting of Shareholders, subject to his continued board service. Settlement will be in shares of common stock on the vesting date or, if elected, on the earlier of the end of his board service, death or disability, or a change in control of the company.
Collegium Pharmaceutical director John Gordon Freund reported several equity transactions. On May 15, 2026, he sold 4,127 shares of common stock in an open-market trade at $34.54 per share and exercised stock options to acquire 8,700 shares at $16.49 per share. Following these transactions, he directly holds 83,972 common shares. On May 14, 2026, he also received a grant of 8,741 restricted stock units (RSUs), which vest on the earlier of May 14, 2027 or the company’s 2027 annual meeting, subject to continued board service. In addition, filings show indirect holdings of 23,129 shares through John Freund Family Partnership IV, L.P. and 8,625 shares through Skyline Venture Management V, LLC, where he shares voting and investment power and disclaims beneficial ownership beyond his proportionate pecuniary interest.
BOHLIN GAREN G reported acquisition or exercise transactions in this Form 4 filing.
Collegium Pharmaceutical director Garen G. Bohlin received an equity award in the form of restricted stock units. The grant covers 8,741 RSUs, each representing one share of common stock, increasing his direct holdings to 71,000 shares. The RSUs vest on the earlier of May 14, 2027 or the company’s 2027 Annual Meeting of Shareholders, contingent on continued board service. Settlement will occur in shares of common stock at vesting or, if elected, upon the end of board service, death, disability, or a change in control.
Glancy Donovan Michael reported acquisition or exercise transactions in this Form 4 filing.
COLLEGIUM PHARMACEUTICAL, INC director Michael Glancy was granted 17,482 restricted stock units on May 14, 2026 at no cash cost. Two equal tranches of 8,741 RSUs are scheduled to vest around May 14, 2027, contingent on continued board service, leaving him with 17,482 shares reported following the grant.
Balice-Gordon Rita J. reported acquisition or exercise transactions in this Form 4 filing.
COLLEGIUM PHARMACEUTICAL director Rita J. Balice-Gordon received an equity grant in the form of restricted stock units (RSUs). The award covers 8,741 RSUs, each representing one share of common stock, and increases her direct holdings to 61,370 shares after the transaction.
The RSUs vest on the earlier of May 14, 2027, or the company’s 2027 Annual Meeting of Shareholders, as long as she continues serving as a director. Settlement occurs in shares on that vesting date or, if she elects, at the end of her board service, upon death or disability, or upon a change in control of the company.
SANTINI GINO reported acquisition or exercise transactions in this Form 4 filing.
COLLEGIUM PHARMACEUTICAL director Gino Santini received an equity award of 8,741 restricted stock units (RSUs) of common stock on May 14, 2026. Each RSU represents one share of common stock at no purchase price.
The RSUs vest on the earlier of May 14, 2027, or the company’s 2027 Annual Meeting of Shareholders, if he continues serving as a director. Settlement can occur then or, if he elects, at the end of his board service, upon death or disability, or upon a change in control. Following this grant, he directly holds 103,783 shares.
Collegium Pharmaceutical director Nancy Lurker reported an open-market sale of Common Stock. On May 13, 2026, she sold 4,500 shares at a weighted average price of $35.9691 per share, in multiple trades between $35.55 and $36.50. After this transaction, she directly holds 18,017 shares of Collegium Pharmaceutical common stock.
Collegium Pharmaceutical director Garen G. Bohlin exercised stock options and sold the resulting shares in a same-day transaction. On May 11, 2026, Bohlin exercised options for 8,700 shares of common stock at $16.49 per share, then completed an open-market sale of 8,700 shares at a weighted average price of $37.1829 per share. The sale price reflects multiple trades between $37.18 and $37.43. After these transactions, Bohlin directly holds 62,259 shares of Collegium Pharmaceutical common stock, with the exercised option position reduced to zero.
Collegium Pharmaceutical executive David Dieter reported a routine share disposition tied to tax withholding. On the vesting of restricted stock units, 8,840 shares of common stock were withheld by the company at $35.72 per share to cover applicable withholding taxes. After this non-market transaction, he directly holds 68,231 shares of Collegium Pharmaceutical common stock.
COLLEGIUM PHARMACEUTICAL, INC. executive vice president and general counsel David Dieter reported an open-market sale of 13,976 shares of common stock on March 18, 2026 at a weighted average price of $34.9241 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, and executed through multiple trades between $34.74 and $35.39. Following this transaction, Dieter directly holds 77,071 shares of Collegium common stock.
Collegium Pharmaceutical EVP & General Counsel David Dieter sold 6,224 shares of common stock at $36.65 per share in an open-market transaction. After this sale, he directly holds 91,047 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating it was scheduled in advance rather than timed discretionarily.
COLLEGIUM PHARMACEUTICAL, INC executive Scott Dreyer, EVP & Chief Commercial Officer, reported open-market sales of the company’s common stock. On March 3, 2026, he sold 46,417 shares at a weighted average price of $40.3636 per share and 3,559 shares at a weighted average price of $40.9889 per share.
These sales, totaling 49,976 shares, were effected pursuant to a Rule 10b5-1 trading plan adopted by Dreyer on September 3, 2025. After the reported transactions, he held 71,770 shares of common stock directly.
Pharmaceutical, Inc. executive vice president and general counsel David Dieter reported several equity compensation transactions. He acquired 22,194 restricted stock units at $0 and 9,005 performance share units after performance goals were confirmed, also at $0. To cover tax withholding on vested performance units, 2,781 shares were disposed of at $46.75. After these transactions, he directly owned 97,271 shares of common stock. The new RSUs vest one-third on February 10, 2027, with the remainder vesting in equal annual installments over the following two years, contingent on his continued service.
Pharmaceutical, Inc.'s President, CEO and director Vikram Karnani reported equity compensation transactions in the company’s common stock. On February 10, 2026, he received a grant of 79,264 restricted stock units, each representing one future share, at a price of $0 per share.
On the same date, 32,531 performance share units from the 2025 fiscal year vested after performance criteria were met, increasing his direct holdings. The company withheld 11,296 shares at $46.75 per share to cover tax obligations tied to the vesting, leaving Karnani with 197,864 shares of common stock owned directly after these transactions.
Pharmaceutical, Inc.’s EVP and Chief Medical Officer Thomas B. Smith reported equity compensation changes on February 10, 2026. He received 14,268 restricted stock units with no cash paid and 22,774 performance share units that vested after performance goals were certified.
One-third of the new RSUs will vest on February 10, 2027, with the rest vesting in equal annual installments over the next two years, subject to continued service. To cover withholding taxes on the PSU and RSU vesting, 5,897 and 11,538 shares, respectively, were withheld at $46.75 per share, leaving him with 90,651 common shares owned directly.
Pharmaceutical, Inc. Executive Vice President and Chief Financial Officer Colleen Tupper reported equity compensation activity in common stock. On February 10, 2026, she acquired 26,421 restricted stock units and 32,734 performance share units at no cost, reflecting new stock-based awards and vesting.
To cover tax withholding on these vestings, 11,861 shares and 26,679 shares were withheld at a price of $46.75 per share rather than sold in the open market. After these grant, vesting, and withholding transactions, she directly beneficially owned 147,282 shares of common stock.
Pharmaceutical, Inc.'s EVP & Chief Commercial Officer Scott Dreyer reported equity awards and related tax withholding transactions in common stock on February 10, 2026. He acquired 19,023 restricted stock units and 30,702 performance share units at a stated price of $0 per share.
The performance share units reflect previously granted awards that vested after performance criteria were met. The company withheld 9,977 and 21,615 shares at $46.75 per share to cover tax obligations on these vestings. After these grants and withholdings, Dreyer directly owned 121,746 shares of common stock.
Collegium Pharmaceutical (COLL) Form 4: Director John A. Fallon, MD exercised options and sold shares on 11/12/2025. He exercised stock options for 15,000 shares at $16.49 and 19,853 shares at $9.33, then sold 34,853 shares at a weighted average price of $47.2136.
Following these transactions, he directly beneficially owned 64,634 shares. A footnote states the sale occurred in multiple trades between $46.805 and $47.51. The reported options were fully vested and exercisable, and the specific option positions exercised now show 0 remaining.
Collegium Pharmaceutical (COLL) reported an insider transaction by its EVP & Chief Financial Officer. On 11/06/2025, the officer sold 25,142 shares of common stock at a weighted average price of $40.3801 and a separate tranche of 4,858 shares at a weighted average price of $41.2756, totaling 30,000 shares. Following these sales, the officer beneficially owned 126,667 shares, held directly.
The sales were made pursuant to a Rule 10b5-1 trading plan adopted on May 30, 2025, with prices executed across ranges of $40.00–$40.98 and $41.00–$41.75, as disclosed.